Sunday 18 October 2026
Export IVF’s income statement to Excel — free account
INVO Fertility, Inc
IVF Healthcare Medical Devices
INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS grew 100.1%, free cash flow grew 35.1% and total debt fell 50.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.56
0.03
−5.08%
Follow IVF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.53 | 0.62 | 0.06 | 0.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.63) | (2.32) | 17.50 | (1.48) | |
P/B ratio |
0.25 | 0.30 | 0.09 | 0.00 | |
Price to Tangible BV |
0.73 | 0.66 | 0.00 | 0.00 | |
EV/Sales |
0.12 | 0.05 | (0.11) | 0.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.14 | 0.00 | |
EV/Operating CF |
(0.20) | (0.07) | 0.11 | (0.44) | |
EV/FCF |
(0.19) | (0.07) | 0.11 | (0.43) | |
Quick Ratio |
0.61 | 0.81 | 0.22 | 0.07 | |
Current Ratio |
0.71 | 0.90 | 0.27 | 0.12 | |
Net Debt/EBITDA |
2.81 | 2.93 | 5.91 | (0.43) | |
Debt/Assets |
1.99% | 2.68% | 3.68% | 5.85% | |
Debt/Equity |
0.03 | 0.04 | 0.10 | 0.19 | |
Asset Turnover |
0.33 | 0.26 | 0.21 | 0.39 | |
Operating CF/Net income |
(1.24) | 0.35 | (0.02) | 0.67 | |
Capex/Depreciation |
(0.13) | 0.00 | (0.01) | 0.10 | |
Interest Coverage |
(7.28) | (8.82) | (3.46) | (11.22) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
87.65% | 107.98% | 114.49% | 121.11% | |
Intangible Assets out of Total Assets |
0.41 | 0.32 | 0.36 | 0.39 | |
Share Based Compensation of Revenue |
1.12% | 3.52% | 8.86% | 27.40% | |
Graham Net Nets |
(1.18) | (0.87) | (23.20) | (4.52) | |
Graham Number |
791.09 | 790.11 | 1,220.36 | 1,578.39 | |
Earnings Yield |
191,589.05% | 114,256.32% | 42,636.66% | (10,366.64%) | |
Free Cash Flow Yield |
(120.45%) | (121.90%) | (1,600.54%) | (296.49%) | |
Revenue per Share |
1.03 | 1.23 | 13.53 | 20.38 | |
Operating CF per Share |
(0.52) | (1.17) | 0.22 | (20.61) | |
Capex per Share |
(0.01) | 0.00 | (0.10) | (0.09) | |
Free Cash Flow per Share |
(0.53) | (1.17) | 0.11 | (20.70) | |
Cash per Share |
1.77 | 2.99 | 17.76 | 4.13 | |
Shareholders Equity per Share |
7.83 | 9.17 | 61.75 | 67.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.83 | 9.17 | 61.75 | 67.85 | |
Free Cash Flow |
(1.12) | (1.92) | 0.01 | (1.78) | |
Working Capital |
(1.92) | (0.62) | (7.57) | (8.11) | |
Capital Expenditures |
(0.02) | — | (0.01) | (0.01) | |
Net Current Asset Value |
(4.74) | (3.90) | (10.23) | (11.85) | |
EV/EBIT |
0.00 | 0.00 | 0.10 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.25 | 0.21 | 0.17 | 0.27 | |
Average Payables |
1.91 | 3.23 | 2.57 | 2.52 | |
Average Inventory |
0.23 | 0.22 | 0.22 | 0.22 | |
Average Assets |
22.58 | 28.20 | 33.15 | 17.93 | |
Average Common Equity |
4.30 | (6.21) | (6.49) | (5.35) |
Columns are period end dates